Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CTSA | P10619 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL455687 | 0.84 | KDM4E (0.59) | ALDH1A1KDM4EALOX15TSHRACMSD | |
| SCHEMBL3552924 | 0.82 | KDM4E (0.46) | GRM4KDM4EALOX15TSHRACMSD | |
| SCHEMBL6641842 | 0.81 | KDM4E (0.56) | ALDH1A1KDM4EALOX15TSHRACMSD | |
| Hydrochloric Acid SCHEMBL27613793 | 0.81 | KDM4E (0.56) | ALDH1A1KDM4EALOX15TSHRACMSD | |
| SCHEMBL29723811 | 0.80 | KDM4E (0.70) | GRM4KDM4EALOX15TSHRACMSD | |
| SCHEMBL107964 | 0.80 | KDM4E (0.70) | GRM4KDM4EALOX15TSHRACMSD | |
| Hydrochloric Acid SCHEMBL28930333 | 0.79 | ALDH1A1 (0.58) | ALDH1A1KDM4EALOX15TSHRACMSD | |
| SCHEMBL28026227 | 0.78 | GRM4 (0.38) | GRM4KDM4EALOX15TSHRACMSD | |
| Hydrochloric Acid SCHEMBL11682457 | 0.78 | KDM4E (0.67) | GRM4KDM4EALOX15TSHRACMSD | |
| SCHEMBL3956769 | 0.78 | GRM4 (0.45) | ALDH1A1GRM4KDM4EALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120051457-A | Oxalic acid amide compound, pharmaceutical composition containing oxalic acid amide compound, preparation method and application of oxalic acid amide compound | 四川科伦博泰生物医药股份有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-118420523-A | Pyridine derivative and application thereof in medicine | 成都百裕制药股份有限公司 | 2024-08-02 | — | — | CN | disclosed |
| WO-2023110843-A1 | HETEROBICYCLIC DERIVATIVES AS ITK INHIBITORS | ALMIRALL, S.A. (ES) | 2023-06-22 | — | — | WO | disclosed |
| US-20230002426-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | RECURIUM IP HOLDINGS, LLC | 2023-01-05 | — | — | US | disclosed |
| US-20220009938-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| WO-2021097139-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | RECURIUM IP HOLDINGS, LLC (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20200377474-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-12-03 | — | — | US | disclosed |
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9701635-B2 | C-H fluorination of heterocycles with silver (II) fluoride | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | UNIV PRINCETON (US) | 2016-12-01 | — | — | US | disclosed |
| US-7615643-B2 | 3-[((1R)-1-{2-Chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl}ethyl)oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide; polo like kinase enzyme inhibitors; anticarcinogenic agents for treating cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615643-B2 | 3-[((1R)-1-{2-Chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl}ethyl)oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide; polo like kinase enzyme inhibitors; anticarcinogenic agents for treating cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615643-B2 | 3-[((1R)-1-{2-Chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl}ethyl)oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide; polo like kinase enzyme inhibitors; anticarcinogenic agents for treating cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090124615-A9 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2009-05-14 | — | — | US | disclosed |
| US-20090124615-A9 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2009-05-14 | — | — | US | disclosed |
| US-20090124615-A9 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2009-05-14 | — | — | US | disclosed |
| US-20080300247-A1 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2008-12-04 | — | — | US | disclosed |
| US-20080300247-A1 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2008-12-04 | — | — | US | disclosed |
| US-20080300247-A1 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | ALDH1A1 1469/4885GRM4 1984/4885KDM4E 2299/4885 |
| US-20090124615-A9 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | ALDH1A1 1060/4885GRM4 4054/4885KDM4E 526/4885 |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | ALDH1A1 1469/4885GRM4 1984/4885KDM4E 2299/4885 |
| US-20080300247-A1 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | ALDH1A1 1060/4885GRM4 4054/4885KDM4E 526/4885 |
| US-20200377474-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | BRDT, BRD4, BRD3 | ALDH1A1 1617/4885GRM4 1907/4885KDM4E 260/4885 |
| US-20230002426-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | ADH1A, ADH1C, ADH5 | ALDH1A1 149/4885GRM4 3695/4885KDM4E 1861/4885 |
| US-20220009938-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SCN11A, SCN10A, SCN3A | ALDH1A1 3205/4885GRM4 434/4885KDM4E 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.